Literature DB >> 8068881

Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis.

P Keshaviah1, P F Emerson, E F Vonesh, J C Brandes.   

Abstract

A peritoneal dialysate fill volume of 2 L has become the standard of clinical practice, but the relationships between body size, fill volume, and mass transfer area coefficient (KoA) have not been well established. These relationships were studied in 10 stable peritoneal dialysis patients who underwent six peritoneal equilibration studies (2 h each) at fill volumes of 0.5, 1, 1.5, 2, 2.5, and 3 L. The concentration-time profiles for urea, creatinine, and glucose were measured at each fill volume, and residual volumes were calculated from the preceding dwell period. A modified Henderson equation was used to calculate the KoA for the three solutes as a function of fill volume. By normalizing the KoA for each solute to the value at 2 L, the data for all three solutes collapsed onto the same trend line when plotting the normalized KoA versus dialysate volume. Between 0.5- and 2-L fill volumes, the average normalized KoA increases in an almost linear fashion, its value almost doubling over this range. Between 2- and 3-L fill volumes, there is less than a 10% change in the normalized KoA. However, fill volumes for peak urea KoA were found to increase with increasing body surface area (R = 0.76), being around 2.5 L for an average-sized patient and increasing to between 3 and 3.5 L for body surface areas > 2 m2. To maximize solute transport, these relationships between body size, volume, and KoA should be considered when choosing fill volumes for continuous ambulatory peritoneal dialysis and automated peritoneal dialysis and when deciding reserve and tidal volumes for tidal peritoneal dialysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8068881     DOI: 10.1681/ASN.V4101820

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  13 in total

1.  Body size, not sex, is responsible for differences in type of dialysis.

Authors:  C Florakas; M Godwin; R Morton; R Wilson; E Toffelmire
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

Review 2.  Peritoneal dialysis prescription in children: bedside principles for optimal practice.

Authors:  Michel Fischbach; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

3.  Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy.

Authors:  S J Valle; N A Alzahrani; W Liauw; P H Sugarbaker; A Bhatt; D L Morris
Journal:  Indian J Surg Oncol       Date:  2016-02-05

4.  Automated peritoneal dialysis prescriptions for enhancing sodium and fluid removal: a predictive analysis of optimized, patient-specific dwell times for the day period.

Authors:  Alp Akonur; Steven Guest; James A Sloand; John K Leypoldt
Journal:  Perit Dial Int       Date:  2013 Nov-Dec       Impact factor: 1.756

5.  Impact of fill volume on ultrafiltration with icodextrin in children on chronic peritoneal dialysis.

Authors:  Sharon Rousso; Tonny M Banh; Susan Ackerman; Elizabeth Piva; Christoph Licht; Elizabeth A Harvey
Journal:  Pediatr Nephrol       Date:  2016-05-13       Impact factor: 3.714

6.  Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer.

Authors:  Paul H Sugarbaker; Kurt Van der Speeten; O Anthony Stuart
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

7.  Peritoneal membrane recruitment in rats: a micro-computerized tomography (muCT) study.

Authors:  Laure Bergua; Elodie Breton; Philippe Choquet; Mariette Barthelmebs; Borje Haraldson; Jean-Jacques Helwig; André Constantinesco; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2008-07-18       Impact factor: 3.714

8.  Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration.

Authors:  Akul Singhania; Sherry Y Wu; Nigel A J McMillan
Journal:  J Drug Deliv       Date:  2011-06-07

Review 9.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03

10.  Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy.

Authors:  Joshua C Leinwand; Gleneara E Bates; John D Allendorf; John A Chabot; Sharyn N Lewin; Robert N Taub
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.